12 Affordable Biotech Stocks to Invest In Now

Page 7 of 11

5. Royalty Pharma Plc (NASDAQ:RPRX)

Forward P/E: 8.12

Number of Hedge Fund Holders: 30

Royalty Pharma Plc (NASDAQ:RPRX) is one of the best affordable biotech stocks to invest in now. On September 12, TD Cowen analyst Michael Nedelcovych maintained a Buy rating on Royalty Pharma Plc (NASDAQ:RPRX), keeping the price target at $42.00.

The analyst based the optimistic rating on the company’s promising outlook and strong performance, stating that it consistently surpassed key metrics and is set to meet or exceed its ambitious revenue target of $4.7 billion by 2030.

Nedelcovych added that Royalty Pharma Plc’s (NASDAQ:RPRX) thriving biopharma ecosystem lends it a strategic position as it increasingly relies on royalty financing.

Royalty Pharma Plc (NASDAQ:RPRX) is a funder of innovation in the biopharmaceutical industry and a buyer of biopharmaceutical royalties. It collaborates with innovators from research hospitals, non-profits, and academic institutions through small and mid-cap biotech companies to global pharma companies.

The company funds innovation in the industry both directly, by partnering with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly, by acquiring existing royalties from the original innovators.

Royalty Pharma Plc’s (NASDAQ:RPRX) portfolio includes royalties in over 35 commercial products, including Johnson & Johnson’s Tremfya, AbbVie and Johnson & Johnson’s Imbruvica, Novartis’ Promacta, Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and others.

Page 7 of 11